trial · primary record
Dupilumab
Atopic Dermatitis
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 880 |
| Primary completion | 2026-10-09 |
| Primary endpoint | Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit |
| Registry ID | NCT02612454 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:57.607Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02612454
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.